Riboflavin (Vitamin B2)
Of 9,935 on-market riboflavin (vitamin b2) products in the January 2026 DSLD dump, the median declared dose is 3.4 mg, and 92.1% list Riboflavin as the primary form.
Form share
Of 9,366 products with an identifiable primary form, here is the share held by each form of Riboflavin (Vitamin B2) on the market today.
| Form | Quality tier | n | Share |
|---|---|---|---|
| Riboflavin | Tier 1 | 8,626 | 92.1% |
| Riboflavin 5'-Phosphate (FMN) | Tier 2 | 740 | 7.9% |
Form share over time
Entry-year breakdown of the top forms, 2012–2025.
Dose distribution
Deciles of declared dose per serving (mg), among 9,178 products with a disclosed amount, against the RDA of 1.3.
- 95.3% of products fall below the fairy-dust threshold (80 mg, 20% of the studied low dose).
- 0.5% of products don't disclose an amount because Riboflavin (Vitamin B2) is declared inside a proprietary blend.
By dosage form
By target group
Top brands
Forms explained
A classic PK study found equimolar oral doses of riboflavin and riboflavin-5'-phosphate produce the same urinary riboflavin recovery -- FMN is dephosphorylated to riboflavin before/during absorption, undercutting claims that the phosphorylated form is inherently more bioavailable.
Source: Jusko WJ, Levy G. 1967, J Pharm Sci, PMID 6030496
Elemental fraction: 82.5% (riboflavin-equivalent, free-acid FMN MW 456.35 vs riboflavin MW 376.37 (both confirmed PubChem formulas); the commercial sodium-salt/hydrate form will have a somewhat lower fraction -- approximation)
Per the same PK study, FMN is not shown meaningfully more bioavailable than plain riboflavin in humans at typical doses -- despite marketing as the "active coenzyme form," treated as functionally comparable rather than clearly superior. The widely-repeated "1.3-1.7x more bioavailable" marketing claim could not be traced to a verifiable primary RCT.
Source: Jusko WJ, Levy G. 1967, PMID 6030496
Reference values
- RDA (adult): 1.3 mg — 1.3mg (men); 1.1mg (women), ages 19+
- Tolerable Upper Intake Level (adult): not established — Not established -- no adverse effects reported from high riboflavin intake (up to 400mg/day for 3+ months studied)
- Studied clinical dose range: 400–400 mg
- Schoenen J et al. 1998, Neurology 50(2):466-470, PMID 9484373 -- RCT (n=55), riboflavin 400mg/day reduced migraine attack frequency and headache days vs placebo (59% responder rate vs 15%, p=0.002). Only dose level tested in this pivotal trial -- not a range.